Rheumatoid Factor and Anti-CCP Titers in COVID-19.

Infectious disorders drug targets Pub Date : 2025-09-12 DOI:10.2174/0118715265361107250829044505

Mudathir Abdelshafea Abdelkareem Abakar, Mohamed Ibrahim Awadab, Zohair Khalid Ibrahim Elaraki, Mohammed Elsheikh Osman, Mohamed Ahmed Ibrahim-Holi, Eltayib Hassan Ahmad-Abakur, Tarig M S Alnour

{"title":"Rheumatoid Factor and Anti-CCP Titers in COVID-19.","authors":"Mudathir Abdelshafea Abdelkareem Abakar, Mohamed Ibrahim Awadab, Zohair Khalid Ibrahim Elaraki, Mohammed Elsheikh Osman, Mohamed Ahmed Ibrahim-Holi, Eltayib Hassan Ahmad-Abakur, Tarig M S Alnour","doi":"10.2174/0118715265361107250829044505","DOIUrl":null,"url":null,"abstract":"Introduction: The mechanisms of Coronavirus Disease 2019 (COVID-19) remain not fully elucidated. The present study aimed to trace the presence of autoantibodies among COVID-19 patients and to determine the association between COVID-19 and these antibodies.Methods: This study is a cross-sectional, hospital-based study involving 90 participants, who were arranged into three groups: the COVID-19 group, the rheumatoid arthritis group, and the control group. The study population was tested for serum concentration of rheumatoid factor and anti-CCP antibodies.Results: The results showed significant elevations in serum levels of rheumatoid factor (P < 0.000) and anti-CCP (P < 0.000) among the rheumatoid arthritis group. Similar findings of a significant increase in rheumatoid factor (P < 0.000) were observed among the COVID-19 group compared to the control group, while an insignificant increase (P = 0.605) was reported between the Anti-CCP and COVID-19 groups.Discussion: The present study revealed a significant increase in rheumatoid factors among the COVID-19 group compared to the healthy control group. These results suggested that COVID-19 contributes to the development of autoantibodies, which might play a critical role in the pathogenesis of COVID-19.Conclusion: These findings suggest that the rheumatoid factor plays a crucial role in the pathogenesis of COVID-19 infection.","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715265361107250829044505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The mechanisms of Coronavirus Disease 2019 (COVID-19) remain not fully elucidated. The present study aimed to trace the presence of autoantibodies among COVID-19 patients and to determine the association between COVID-19 and these antibodies.

Methods: This study is a cross-sectional, hospital-based study involving 90 participants, who were arranged into three groups: the COVID-19 group, the rheumatoid arthritis group, and the control group. The study population was tested for serum concentration of rheumatoid factor and anti-CCP antibodies.

Results: The results showed significant elevations in serum levels of rheumatoid factor (P < 0.000) and anti-CCP (P < 0.000) among the rheumatoid arthritis group. Similar findings of a significant increase in rheumatoid factor (P < 0.000) were observed among the COVID-19 group compared to the control group, while an insignificant increase (P = 0.605) was reported between the Anti-CCP and COVID-19 groups.

Discussion: The present study revealed a significant increase in rheumatoid factors among the COVID-19 group compared to the healthy control group. These results suggested that COVID-19 contributes to the development of autoantibodies, which might play a critical role in the pathogenesis of COVID-19.

Conclusion: These findings suggest that the rheumatoid factor plays a crucial role in the pathogenesis of COVID-19 infection.

查看原文本刊更多论文

COVID-19的类风湿因子和抗ccp滴度。

2019冠状病毒病（COVID-19）的发病机制尚未完全阐明。本研究旨在追踪COVID-19患者中自身抗体的存在，并确定COVID-19与这些抗体之间的关系。方法：本研究是一项基于医院的横断面研究，涉及90名参与者，分为三组：COVID-19组，类风湿性关节炎组和对照组。对研究人群进行血清类风湿因子和抗ccp抗体浓度检测。结果：类风湿关节炎组血清类风湿因子（rheumatoid factor）和抗ccp （anti-CCP）水平均显著升高（P < 0.000）。与对照组相比，COVID-19组类风湿因子显著升高（P < 0.000），而Anti-CCP组与COVID-19组之间的类风湿因子升高不显著（P = 0.605）。讨论：本研究显示，与健康对照组相比，COVID-19组的类风湿因子显著增加。这些结果表明，COVID-19促进自身抗体的产生，这可能在COVID-19的发病机制中起关键作用。结论：这些结果提示类风湿因子在COVID-19感染的发病机制中起重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets

自引率

0.00%

发文量